Huntleigh Advisors Inc. Has $1.47 Million Stock Holdings in GeneDx Holdings Corp. (NASDAQ:WGS)

Huntleigh Advisors Inc. lowered its stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 53.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,567 shares of the company's stock after selling 19,363 shares during the period. Huntleigh Advisors Inc. owned 0.06% of GeneDx worth $1,467,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in WGS. Principal Financial Group Inc. raised its holdings in shares of GeneDx by 354.5% in the 1st quarter. Principal Financial Group Inc. now owns 71,584 shares of the company's stock valued at $6,340,000 after purchasing an additional 55,833 shares during the period. Teacher Retirement System of Texas bought a new stake in GeneDx in the first quarter valued at approximately $264,000. KBC Group NV bought a new stake in GeneDx in the first quarter valued at approximately $81,000. Allspring Global Investments Holdings LLC lifted its position in shares of GeneDx by 111.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 190,297 shares of the company's stock valued at $16,097,000 after buying an additional 100,146 shares during the last quarter. Finally, Chung Wu Investment Group LLC bought a new position in shares of GeneDx during the 1st quarter worth approximately $270,000. Institutional investors and hedge funds own 61.72% of the company's stock.

Insider Buying and Selling

In related news, CEO Katherine Stueland sold 9,657 shares of the business's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $90.94, for a total value of $878,207.58. Following the completion of the transaction, the chief executive officer owned 4,940 shares of the company's stock, valued at $449,243.60. The trade was a 66.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Kevin Feeley sold 1,344 shares of the stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $91.12, for a total transaction of $122,465.28. Following the sale, the chief financial officer owned 7,425 shares in the company, valued at $676,566. The trade was a 15.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 76,023 shares of company stock valued at $6,920,533 over the last 90 days. 29.60% of the stock is owned by corporate insiders.

GeneDx Stock Performance

Shares of WGS stock traded up $1.82 on Friday, hitting $91.61. The company's stock had a trading volume of 328,245 shares, compared to its average volume of 816,175. GeneDx Holdings Corp. has a fifty-two week low of $25.32 and a fifty-two week high of $117.75. The company has a market capitalization of $2.61 billion, a PE ratio of 100.67 and a beta of 2.01. The stock's 50 day moving average is $73.74 and its 200-day moving average is $82.26. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.07 and a current ratio of 3.25.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.17. GeneDx had a negative net margin of 11.69% and a positive return on equity of 10.17%. The firm had revenue of $87.12 million for the quarter, compared to analyst estimates of $79.90 million. Equities research analysts expect that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Wall Street Zen cut GeneDx from a "buy" rating to a "hold" rating in a research note on Saturday, June 21st. Wells Fargo & Company decreased their price objective on shares of GeneDx from $105.00 to $78.00 and set an "equal weight" rating on the stock in a report on Thursday, May 1st. Jefferies Financial Group upgraded shares of GeneDx from a "hold" rating to a "buy" rating and set a $80.00 target price for the company in a research note on Friday, May 9th. Guggenheim reaffirmed a "buy" rating and set a $115.00 target price (up previously from $88.00) on shares of GeneDx in a report on Monday. Finally, TD Securities lowered their price target on shares of GeneDx from $135.00 to $110.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $90.13.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.